Gilead Sciences, Inc.

(NASDAQ Global Select)
Back to all articles
Very Bullish +85

Gilead Sciences's Q1 2026 Earnings: What to Expect - Yahoo Finance

AI-generated analysis

📈 Gilead Sciences (GILD) has a market capitalization of $173 billion and specializes in HIV-1 treatment medications.

💰 Analysts expect Q1 2026 diluted EPS to reach $1.86, representing a 2.8% increase from the previous year's quarter.

📊 The company has exceeded Wall Street earnings estimates in three of its last four quarters with only one miss.

🔮 Full-year fiscal 2026 EPS is projected at $8.66, with further growth to $9.63 expected by fiscal 2027.

🚀 GILD stock has outperformed the S&P 500 and healthcare ETF sectors over the past 52 weeks with a 26.1% gain.

💵 Q4 2025 earnings recently beat forecasts, reporting revenue of $7.9 billion and adjusted EPS of $1.86.

👀 Full-year earnings guidance for 2026 is anticipated to range between $8.45 and $8.85 per share.

🎯 Analyst sentiment remains highly bullish, with the majority of coverage rating the stock as a "Strong Buy."

🏆 Approximately two-thirds of the 32 analysts covering GILD recommend either a "Strong" or "Moderate Buy."

📉 The average analyst price target is $158.86, suggesting potential upside of 14.2% from current levels.

Bullish Signals
  • Gilead Sciences has achieved strong performance in its latest earnings, with EPS of $1.86 exceeding Wall Street forecasts and revenue reaching $7.9 billion.
  • The company has exceeded analyst expectations in three out of its last four quarters, demonstrating consistent positive momentum.
  • Analysts project significant growth for GILD, with full fiscal 2026 EPS expected to reach $8.66, up 6.3% from fiscal 2025, and further rising to $9.63 in fiscal 2027 (11.2% YoY).
  • GILD stock has outperformed major benchmarks, rising 26.1% over the past 52 weeks compared to the S&P 500's 16.4% gain.
  • Analysts maintain a 'Strong Buy' rating overall, with 22 out of 32 analysts recommending 'Strong Buy' for the stock.
  • The average analyst price target is $158.86, indicating a bullish upside of 14.2% from current levels.
Risk Factors
  • The company has missed Wall Street's EPS estimates once in its last four quarters, indicating potential inconsistency with earnings growth.
  • Analyst sentiment is mixed with eight analysts suggesting a 'Hold' rating, implying some investors believe the current valuation may not fully reflect future risks.
  • While EPS is projected to grow, fiscal 2026 revenue of $8.45 to $8.85 per share could face pressure from competitive HIV-1 treatment markets.
  • Stock price volatility is evident given the significant rise on single earnings releases, potentially signaling sensitivity to market or geopolitical events unrelated to core business.
  • Gilead's heavy reliance on HIV-1 treatments (Biktarvy, Descovy, etc.) may limit growth diversification as newer therapies face patent cliffs or generic competition.
Full Analysis
Gilead Sciences, Inc., based in Foster City, California, is a leading biopharmaceutical company with a market capitalization of $173 billion. The firm specializes in developing medicines for unmet medical needs globally and offers a portfolio including Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and Yeztugo for HIV-1 treatment. Investors are anticipating the release of its Q1 2026 earnings shortly, with analysts expecting diluted EPS of $1.86, representing a 2.8% increase from $1.81 in the year-ago quarter. The company has demonstrated strong consistency recently, exceeding Wall Street's EPS estimates in three of its last four quarters. Performance metrics highlight significant growth for GILD over recent periods; the stock has risen 26.1% over the past 52 weeks, significantly outpacing the S&P 500 Index's 16.4% gain and the State Street Healthcare Select Sector SPDR ETF's 2.9% rise. Following its Q4 2025 earnings on Feb. 11, GILD stock climbed 5.8%, with reported revenue reaching $7.9 billion and adjusted EPS of $1.86, both surpassing market forecasts. For fiscal year 2026, analysts project an EPS of $8.66, up 6.3% from the previous year's $8.15, while estimates for fiscal 2027 indicate a further rise to approximately $9.63, marking an 11.2% year-over-year increase. Analyst sentiment remains highly positive regarding the company's trajectory. The stock currently holds a "Strong Buy" overall rating based on a group of 32 analysts covering the ticker. Specifically, 22 analysts recommend a "Strong Buy," two suggest a "Moderate Buy," and eight advise a "Hold." Gilead has set full-year earnings expectations between $8.45 and $8.85 per share for the upcoming period. With an average analyst price target of $158.86, this valuation implies a potential upside of 14.2% from current trading levels. The article notes that as of publication, contributor Aritra Gangopadhyay held no positions in Gild or other securities mentioned, and the content is for informational purposes originally published on Barchart.com.